Previous studies in mouse models have demonstrated that KRAS is capable of initiating pancreatic ductal adenocarcinoma and continuous signalling is required for its progression and maintenance at the primary and metastatic sites [72,73]. This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.